EZH2 Methyltransferase and H3K27 Methylation in Breast Cancer by Yoo, Kyung Hyun & Hennighausen, Lothar
Int. J. Biol. Sci. 2012, 8 
 
 
http://www.biolsci.org 
59 
I In nt te er rn na at ti io on na al l   J Jo ou ur rn na al l   o of f   B Bi io ol lo og gi ic ca al l   S Sc ci ie en nc ce es s   
2012; 8(1):59-65 
Review 
EZH2 Methyltransferase and H3K27 Methylation in Breast Cancer   
Kyung Hyun Yoo
 and Lothar Hennighausen  
Laboratory of Genetics and Physiology, National Institutes of Health, Bethesda, MD, 20892, USA  
 Corresponding author: Kyung Hyun Yoo, Laboratory of Genetics and Physiology, NIH/NIDDK, Bldg. 8, Rm. 107, Be-
thesda, MD 20892, USA. ryuk@mail.nih.gov 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2011.08.16; Accepted: 2011.09.12; Published: 2011.11.18 
Abstract 
Histone modifications are thought to control the regulation of genetic programs in normal 
physiology and cancer. Methylation (mono-, di-, and tri-methylation) on histone H3 lysine (K) 
27 induces transcriptional repression, and thereby participates in controlling gene expression 
patterns. Enhancer of zeste (EZH) 2, a methyltransferase and component of the polycomb 
repressive complex 2 (PRC2), plays an essential role in the epigenetic maintenance of the 
H3K27me3 repressive chromatin mark. Abnormal EZH2 expression has been associated with 
various cancers including breast cancer. Here, we discuss the contribution of EZH2 and the 
PRC2 complex in controlling the H3K27 methylation status and subsequent consequences on 
genomic instability and the cell cycle in breast cancer cells. We also discuss distinct molecular 
mechanisms used by EZH2 to suppress BRCA1 functions. 
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Transcriptional regulation modulated by 
the H3K27 methylation status 
Post-translational  modifications  of  the 
N-terminal tails of core histones, including methyla-
tion, acetylation, ubiquitylation and phosphorylation, 
influence chromatin configuration, which can modu-
late  accessibility  of  transcription  factors  and  tran-
scriptional  activity  of  nearby  genes  [1].  Four  lysine 
residues in the N-terminal tail of histone H3, K4, K9, 
K27 and K36, are primary targets of specific histone 
methyltransferases  and  demethylases.  Methylated 
H3K27  is  abundant,  and  three  different  statues 
(mono-,  di-  or  tri-methylation)  exist.  For  example, 
based  on  quantitative  mass  spectrometry  50%  of 
H3K27 in embryonic stem (ES) cells is dimethylated, 
15% trimethylated and 15% monomethylated [2]. 
H3K27 di- and tri-methylation are characteristic 
of PcG (Polycomb group) target genes and are associ-
ated with transcriptional repression [3]. PRC1 (Poly-
comb repressive complex 1) and PCR2 are associated 
with  chromatin  condensation.  PRC1  catalyzes  the 
monoubiquitylation  of  histone  H2A  and  PRC2  con-
tributes  to  the  methylation  of  H3K27  [4].  PRC2  is 
composed of several proteins, including EED, SUZ12, 
RbAP46/48 and either EZH1 or EZH2. EZH1 and 2 
are characterized by a SET domain, which functions 
as a histone-lysine N-methyltransferases [5-8]. PRC2 
complexes  containing  EZH1  or  EZH2  affect  repres-
sion of gene expression. While PRC2 complexes con-
taining  EZH2  are  primarily  responsible  for  H3K27 
methylation,  PRC2  complexes  containing  EZH1  can 
also  catalyze  H3K27  methylation  [9],  or  compact 
chromatin  through  mechanisms  other  than  histone 
methylation. However, these mechanisms remain to 
be fully explored (Figure 1A) [10].  
Experiments  with  cell-specific  Ezh2  knockout 
mice  have  demonstrated  that  EZH2  influences 
proliferation  and  differentiation  of  stem  cells  and 
progenitor cells in three distinct cell types, adipocytes, 
keratinocytes, and neurons [11-13]. Experimental ev-
idence  from  several  systems  suggests  that  H3K27 
methylation  is  mainly  achieved  by  EZH2  and  to  a 
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lesser  extent  by  EZH1.  The  critical  importance  of 
EZH2 is reflected by the fact that Ezh2-null mice die in 
utero,  while  Ezh1-null  mice  have  no  overt  defects, 
possibly  due  to  compensatory  functions  of  EZH2. 
However, EZH1 can also compensate to some extent 
for EZH2 as loss of both EZH1 and 2 evoke more se-
vere consequences than loss of EZH2 alone [14]. In 
addition, contribution to H3K27 monomethylation by 
G9a, a well-known H3K9 methyltransferase, was ob-
served  in  vitro  and  in  vivo  [15,  16].  Although  no 
changes in H3K27 di- and tri-methylation were  ob-
served between wild type and G9a-/- ES cells, the ex-
tent of monomethylation was significantly decreased 
in G9a -/- ES cells. It is feasible that G9a activity par-
tially compensates for the loss of EZH2. It is possible 
that G9a introduces a monomethyl group on H3K27 
in the absence of EZH2 and that this is sufficient the 
binding by Embryonic Ectoderm Development (EED), 
a component of the PRC2 complex, which contains the 
methyl-lysine histone-binding domain WD40. 
JMJD3  (KDM6B,  [jumonji-domain  containing 
protein  3])  and  UTX  (KDM6A  [Ubiquitously  tran-
scribed tetratricopeptide repeat gene on the X chro-
mosome]) are demethylases acting on H3K27 (Figure 
1B).  They  remove  the  gene-inactivating  H3K27 
di-methyl  and  tri-methyl  marks  and  thereby 
presumably  contribute  to  the  maintenance  of  gene 
expression. Abberant of UTX and JMJD3 levels have 
been  associated  with  cancer  and  defective 
differentiation programs [17].  
 
EZH2 and human breast cancer  
Excessive  EZH2  concentrations  have  been  re-
ported as a marker of aggressive breast cancer [18, 19] 
and associated with invasion and cancer progression. 
Chinnaiyan and colleagues tested EZH2 protein levels 
in 280 breast cancer patients using high-density tissue 
microarray [20]. EZH2 levels were elevated in patients 
with invasive breast carcinoma relative to normal or 
atypical  hyperplasia.  Notably,  increased  expression 
was  already  observed  in  ductal  carcinoma  in  situ 
(DCIS), a precursor of invasive carcinoma [21]. 
 
 
Figure 1. Transcriptional regulation through H3K27 methylation. (A) Transcriptional repression regulated by the 
polycomb repressive complex 2 (PRC2) including EZH1 or EZH2. PRC2 complexes, which include EED, SUZ12, RbAP46/48 
and EZH2, catalyze H3K27 di- and tri-methylation. This in turn leads to a more condensed chromatin state and transcrip-
tional repression. PRC2 complexes containing EZH1 can also catalyze H3K27 methylation, or compact chromatin through 
other mechanism. G9a has H3K27 methyltransferase activity and also affects gene silencing. (B) Transcriptional activation 
regulated by UTX and JMJD3. UTX and JMJD3 are demethylases that form complexes with MLL, RbBP5 and WDR5. The 
removal of methyl groups from H3K27me3 leads to transcriptionally active chromatin. Int. J. Biol. Sci. 2012, 8 
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Figure 2. The biology of EZH2 in breast cancer. EZH2 gene expression is regulated by the HIF, E2F, and RAF/ERK/Elk 
pathways. Increased levels of EZH2 have been linked to H3K27 trimethylation (H3K27me3) on promoter regions of several 
genes (RAD51, RUNX3, CDKN1C (p57
 KIP2), FOXC1, and CDH1 (E-cadherin)) whose expression is decreased. Reduced levels 
of RAD51 lead to the activation of Raf1/ERK and β-catenin signaling. Transcription of the CDKN1A gene is under RUNX3 
control and lower concentrations of RUNX3 result in lower p21
WAF/Cip1 levels, which fail to fully block the cell cycle. The 
CDKN1C gene encodes the cyclin-dependent kinase inhibitor p57
KIP2, a strong inhibitor of cyclinE1 and CDK2 complexes. 
Expression of the CDKN1C gene is regulated through H3K27me3 of its promoter. Reduction of p57
KIP2 leads to accelerated 
G1-S transition, which has been suggested to support breast cancer progression. Accumulation of H3K27me3 in the 
promoters of the FOXC1 gene, a fork head family transcription factor used in developmental programs, and the CDH1 gene, 
that encodes E-cadherin, has been observed in breast cancer cell lines. A decrease of FOXC1 and E-cadherin would be in 
agreement with enhanced cell invasion and metastasis.  
 
Dynamic signaling regulated by EZH2 
Elevated  EZH2  concentration  has  been  associ-
ated with increased tumor cell proliferation in various 
cancers including breast, prostate and melanoma [22]. 
The two-layered regulatory loop includes transcrip-
tional regulation of the EZH2 gene and ensuing con-
sequences of associated H3K27me3 (Figure 2). Three 
well-defined transcription factors have been invoked 
in the regulation of EZH2. E2F, a target of the reti-
noblastoma protein (pRB), plays a critical role in reg-
ulating  cell  cycle  progression  through  activating 
genes that control entry into the S phase and genes 
associated  with  DNA  replication  [23].  Upon  phos-
phorylation of pRB, activated E2F binds to promoter 
regions of EZH2 and EED, and controls their expres-Int. J. Biol. Sci. 2012, 8 
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sion. However, Helin and colleagues confirmed that 
the interrupt of EZH2 and EED expression was not 
enough to increase expression of negative regulators 
of cell cycle including p14ARF, but positive regulators 
of  cell  proliferation,  cyclinD1  (CCND1),  cyclinE1 
(CCNE1),  cyclinA2  (CCNA2)  and  cyclinB1  (CCNB1), 
significantly  decreased  in  EZH2  lacking  cells.  They 
concluded that the PRC complex, including EZH2, is 
required for the activation or maintenance of the ac-
tivated  state  of  certain  genes  in  proliferating  cells 
through H3K27 methylation [24].  
EZH2 expression is also controlled by hypoxia 
through  HIF response elements (HRE) in the  EZH2 
gene  promoter  [25].  In  hypoxic  microenvironment, 
EZH2 expression is increased and thereby promotes 
proliferation  of  breast  tumor  initiating  cells.  Lastly, 
MEK/ERK/Elk  pathway  can  also  leads  to  EZH2 
overexpression in ERBB2-overexpressing breast can-
cer cell lines [26].  
A set of genes associated with cell proliferation 
and  invasion  is  regulated  by  EZH2.  Among  them 
RAD51, RUNX3, and CDKN1C (p57KIP2) regulate cell 
proliferation,  and  FOXC1  and  CDH1  (E-cadherin) 
have  been  linked  to  metastasis.  The  runt-related 
(RUNX)  family  is  associated  with  normal  develop-
ment  and  neoplasia  and  RUNX3  is  an  established 
tumor suppressor gene in gastric cancer [46]. Inacti-
vation  of  RUNX3  expression  through  DNA  hyper-
methylation  has  been  reported  in  various  cancers, 
including those of prostate, lung and pancreas. Nota-
bly,  upon  reducing  EZH2  expression  in  the  MCF-7 
breast cancer cell line, RUNX3 expression was recov-
ered.  RUNX3  expression  also  increased  upon  treat-
ment with the deacetylase inhibitor TSA [27]. It has 
been suggested that RUNX3 down-regulation is con-
trolled  by  H3K27me3  through  EZH2  and  histone 
deacetylation  through  HDAC1.  Even  though  DNA 
methylation affects repression of RUNX3, H3K27me3 
by  EZH2  has  a  critical  role  in  down-regulation  of 
RUNX3. RUNX3 reduction leads to the decrease of the 
cyclin-dependent kinase inhibitor p21WAF/Cip1 expres-
sion, which results in the induction of cell prolifera-
tion in breast cancer [28].  
FOXC1,  a  member  of  the  Forkhead  box  tran-
scription  factor  family,  plays  an  important  role  in 
differentiation. Increased EZH2 influences transcrip-
tional repression of FOXC1 through the accumulation 
of H3K27me3 and diminished acetylation of H3/H4 
in MDA-MB-231 cell lines. Elevated FOXC1 concen-
trations  lead  to  reduced  migration  and  invasion  in 
vitro  and  in  vivo  [29].  The  cyclin-dependent  kinase 
(CDK) inhibitor, CDKN1C (p57KIP2) encodes the tumor 
suppressor  p57KIP2  protein.  Reduced  CDKN1C  ex-
pression in various breast cancer cell lines was asso-
ciated  with  EZH2  overexpression  and  increased 
H3K27me3  [30].  Upon  treatment  with  the  histone 
methylation inhibitor 3-deazaneplanocin A (DZNep), 
recovery of  CDKN1C expression was observed sug-
gesting  a  direct  link  between  H3K27me3  and  tran-
scriptional suppression. The transmembrane receptor 
E-cadherin maintains epithelial cellular adhesion and 
integrity  and  it  has  been  proposed  that  its 
down-regulation leads to enhanced invasion in can-
cer.  In  EZH2-overexpressing  breast  epithelial  cells, 
reduced  CDH1  (E-cadherin)  expression  correlated 
with  H3K27me3  levels  in  the  promoter.  However, 
elevated  expression  of  EZH2  was  not  sufficient  to 
increase  enzymatic  activity  for  H3K27me3  at  the 
CDH1 promoter, which also required HDAC activity. 
Increased HDAC activity leads to the removal of ac-
etyl  groups  from  H3K27,  a  prerequisite  for 
EZH2-controlled  histone  methylation.  Increased 
EZH2 induces reduction of CDH1 expression, and it 
leads to metastasis and invasion in breast cancer as 
well as pancreatic cancer and ovarian cancer [31-33].  
EZH2 also appears to regulate breast tumor ini-
tiating cells (BTICs) through suppressing RAD51 ex-
pression. PHO and GAGA motifs, which are targets 
for PRC2 complexes, are located in the  RAD51 pro-
moter and H3K27me3 coincides with these sites. Re-
duction of RAD51 affects chromosome breaks, dele-
tion and translocation as well as increase of centro-
some  number  and  genome  instability  through  acti-
vated RAF/pERK/ ß-catenin signaling [25].  
 
A BRCA1-EZH2 connection 
Mutations  in  BRCA1  are  a  cause  of  basal  like 
breast carcinomas that are ER, PR and Her2-neu neg-
ative (triple negative) and increased EZH2 concentra-
tions were  found  mainly in basal type  breast carci-
nomas  [34].  Germline  Brca1  mutations  predispose 
women to develop breast cancer, and patients have a 
poor prognosis, in part because BRCA1’s role in DNA 
repair  and  genomic  stability  [35].  Even  though  the 
majority  of  basal  breast  cancers  do  not  carry  Brca1 
germline mutations, reduced concentration of BRCA1 
protein and mRNA levels were reported in these pa-
tients [36]. It has been speculated that the underlying 
cause is promoter methylation or transcriptional re-
pression.  However,  the  mechanisms  causing  de-
creased  BRCA1  expression  in  basal  like  carcinomas 
remains to be established. Figure 3 proposes mecha-
nisms  linking  EZH2  overexpression  and  BRCA1  in 
basal like breast cancer.  
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Figure 3. Molecular interplay between EZH2 and BRCA1 in basal like breast cancer. In ER-negative breast 
cancer cells, elevated EZH2 concentrations block the phosphorylation of BRCA1 (Ser1423). Once the tyrosine phosphatase 
Cdc25C is phosphorylated, it dephosphorylates the cyclinB-bound Cdc2 (CDK1) and thereby triggers entry into mitosis. 
Accumulation of Cdc2 and cyclinB1 results in increased cell proliferation. In addition to its canonical function as a H3K27 
methyltransferase, EZH2 most likely also has non-canonical functions. EZH2 can phosphorylate Akt-1 (Ser473), but not 
Akt-2 and -3, and interact with Akt-1. It leads to reduced nuclear retention of BRCA1. In breast cancer cell lines this leads 
to increased centrosome numbers and genome instability. The EZH2 inhibitor DZNep is more effective on BRCA1-deficient 
cells, and can thus serve as one arm in a therapeutic regimen. 
 
EZH2  is  frequently  overexpressed  in 
ER-negative breast cancer cell lines, and a reduction of 
EZH2 results in suppressed cell proliferation. Biolog-
ical  effects  of  EZH2  knockdowns  were  observed  in 
vivo and in vitro system using xenograft transplanta-
tions. Reduced tumor growth was confirmed in xen-
ograft mouse models injected with EZH2 knockdown 
cells  [37].  EZH2  overexpression  inhibits  BRCA1 
phosphorylation (Ser1423) and thereby promotes an 
increase  of  Cdc25C,  an  essential  player  for  G2/M 
checkpoint control. Once Cdc25C is activated, it in-
duces the activity of the Cdc2/cyclinB1 complex. In 
summary,  elevated  EZH2  concentrations  in 
ER-negative breast cancer cell lines confer increased 
cell proliferation in part possibly through the inhibi-
tion of BRCA1 phosphorylation [37].  
BRCA1 is a nuclear protein involved in numer-
ous  activities,  including  DNA  repair  and  estrogen 
receptor modulation. It has been proposed that Akt-1 
(Ser473), but not Akt-2 and 3, are phosphorylated and 
activated by EZH2 in the EZH2 overexpressing breast 
cancer cell line CAL51, and nuclear location of BRCA1 
protein is suppressed in these cells by a yet to be de-
termined mechanism (Figure 3). This in turn results in 
aberrant  mitoses  with  extra  centrosomes,  and  ge-
nomic instability [38]. Elevated EZH2 concentrations 
were observed in mouse mammary epithelium from 
which the Brca1 gene had been deleted. As a result 
gene  expression  related  to  differentiation  was  sup-
pressed and excessive cell proliferation was promot-
ed. DZNep, a well known as EZH2 inhibitor [47], af-
fects  EZH2  concentrations.  It  was  confirmed  that Int. J. Biol. Sci. 2012, 8 
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BRCA1-deficient cells are more sensitive to DZNep, a 
potential  treatment,  when  compared  with 
BRCA1-proficient cells [39].  
Genome-wide approaches to explore PRC 
Genome-wide approaches have been applied to 
identify  genomic  localizations  and  target  genes  of 
PRC complexes in human and mouse ES cells. This 
system  has  been  explored  using  a  combination  of 
chromatin  immunoprecipitation  (ChIP),  ChIP  on 
CHIP and microarray analyses [40-43]. Transcription 
factors  related  with  developmental  regulation,  in-
cluding  homeobox  protein  (HOX),  GATA  binding 
protein (GATA), and runt related transcription factor 
(RUNX) are regulated by the PRC2 complex in human 
ES cells. [42]. In mouse ES cells, 512 genes regulated 
by PRC1 and 2 were identified. These include genes 
encoding the transcription factor families FOX, SOX, 
GATA and TBX [40]. Moreover, enriched H3K27me3 
was  found  in  proximal  promoter  regions  of  these 
genes,  which  were  also  derepressed  in  Suz12-  and 
Eed-null cells [40, 42] supporting the notion that their 
suppression  is  dependent  on  the  PRC  complex. 
Moreover, the differentiation of ES cells resulted  in 
the activation of these genes.  
ChIP-seq analyses with antibodies against EZH2, 
Ring1B,  H3K4me3  and  H3K27me3  have  been  per-
formed  to  identify  the  conservation  of  chromatin 
states  in  orthologous  genomic  loci  in  human  and 
mouse ES cells [44]. Bivalent promoters, which carry 
H3K4me3  and  H3K27me3  marks,  are  highly  con-
served between mouse and human ES cells. In addi-
tion  to  PRC2,  PRC1  binding  was  identified  in  the 
above  genes.  In  general,  H3K27me3  retention  was 
most pronounced in regions that were  occupied by 
both PRC1 and 2, while poor retention was detected 
on sequences occupied by PRC2 only. These findings 
suggest  that  PRC2  catalyzes  and  regulates  H3K27 
methylation  but  is  not  sufficient  to  maintain  the 
methylation status of respective target genes.  
 Genome-wide  approaches  have  been  used  to 
predict the importance  of the PRC2 complex  in the 
regulation  of  developmental  transcription  through 
H3K27  methylation.  However,  it  is  not  clear  what 
concentration of EZH2 is required to regulate H3K27 
methylation,  and  whether  excess  EZH2  has  other 
functions besides its methyltransferase activity.  
Moving forward using mouse genetics 
The  suggestion  that  excess  EZH2,  and  thereby 
altered histone modifications, leads to a changed ep-
igenetic genomic landscape, and thereby contributes 
to cancer progression, is mainly based on correlative 
studies and cell culture investigations. Although bi-
ochemical  studies  are  capable  of  linking  elevated 
EZH2 concentrations with altered genetic programs in 
cancer, clear genetic evidence is scarce. It will be nec-
essary  to  conduct  decisive  genetic  experiments  in 
mice to link EZH2 to the H3K27 methylation status 
and subsequent genetic programs in relevant breast 
cancer  models,  such  as  mice  carrying  mutant  Brca1 
[45]. It will be necessary to explore breast cancer ini-
tiation and progression in relevant mouse models in 
which H3K27 methylation is disrupted. By ablating 
the Ezh1 and Ezh2 genes in mammary epithelium the 
mammary  genome  will  lack  H3K27me3  marks  and 
upon deletion of the Utx and Jmjd3 genes a persistent 
H3K27me3  should  be  expected.  Such  experiments, 
although  labor  intensive  and  time-consuming,  shall 
provide  definitive  answers  on  the  role  of  H3K27 
methylation in development and the etiology of can-
cer.  
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